C2N Diagnostics has entered the South Korean mark
Author: Michael
An inexpensive FDA-approved epilepsy drug could
New research shows simple daily supplements coul
Late-stage trial results show strong reductions
Scientists, founders, clinicians and consumer he
New machine learning tool turns routine clinic v
Telocyte founder discusses new book and reveals
Human Longevity launches a mobile platform that
Strategic licensing partnership brings fresh cap
Trials begin testing a longer-lasting therapy fo